Neoadjuvant Chemotherapy of 6 Cycles vs 8 Cycles in Node Positve Breast Cancer
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Various regimens and schedule as neoadjuvant chemotherapy regimens were investigated and
sequential treatment of anthracyclines followed by taxanes, which has shown superior
pathologic complete respone (pCR) rate (NSABP-B27 study) is widely used until now.
Considering the proven efficacy and tolerable toxicity of 3 cycles of FEC followed by 3
cycles of Docetaxel (FEC3-D3) compared to FEC 6 cycles in adjuvant chemotherapy (PACS 01
trial), use of FEC3-D3 regimen in neoadjuvant setting will be feasible with acceptable
efficacy and further reduce the duration of neoadjuvant chemotherapy.